Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages investors who have suffered losses in Pacira to contact him directly to discuss their options
If you have bought or acquired securities in Pacira Between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi Partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (extension 1310).
(You can also click here to get more information.)
New York, New York – (Newsfile Corp. – January 26, 2025) – Faruqi & Faruqi, LLP, a leading national security law firm, examines potential claims against Pacira Biosciences, Inc. (“Pacira” or “Company”) (NASDAQ: PCRX ) and reminds the investors of the March 14, 2025 deadline to obtain the role of the senior plaintiff in a securities action for securities submitted against the company.
Faruqi & Faruqi is a leading national security law firm with offices in New York, Pennsylvania, California and Georgia. The company has restored hundreds of millions of dollars for investors since its foundation in 1995. See www.faruqilaw.com.
According to the complaint, Pacira announced on August 9, 2024 that the district court in New Jersey had made its 495 patent invalid, and that even the patent of 495 on the basis of obvious and anticipation had violated the 495 patent. In the complaint it is claimed that this judgment has additional evidence at the court by Pacira shortly after the submission. The court would have no effect on the basis for the decision. In the complaint it is also stated that this judgment is secondary to the judgment of the same court, which affects the construction of Paciras 495 and 336 patents.
According to the complaint, Pacira’s announcement that his 495 patent became invalid surprised investors and analysts as well as they immediately reacted to the revelations. The complaint claims that the price of Pacira’s ordinary shares decreased dramatically. According to the complaint of a final market price of USD 22.36 per share on August 8, 2024, Pacira’s share price fell to a low point of $ 11.70 per share on August 9, 2024, a decrease of over 47% in one day investors .
The leading plaintiff created by the court is the investor with the greatest financial interest in the relief requested by the class, which is appropriate and typical for class members who lead and monitor the legal dispute on behalf of the alleged class. Each member of the alleged class can move the Court of Justice as a senior plaintiff by the lawyer of their election or decide not to do anything and to remain a absent class member. Your ability to participate in a recovery is not influenced by the decision to serve as the main plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone who connects information about the behavior of Pacira to contact the company, including whistleblowers, former employees, shareholders and others.
Lawyer advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Earlier results guarantee or predict no similar result in relation to future affairs. We welcome the opportunity to discuss your special case. All communication is treated confidentially.
To display the source version of this press release, please visit https://www.newsfilecorp.com/release/238359
